archive-org.com » ORG » S » SCIENCEMAG.ORG

Total: 698

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling | Science Translational Medicine
    or to prevent resistance To investigate this further we developed isogenic TKI sensitive and TKI resistant pairs of cell lines that mimic the behavior of human tumors We determined that the drug sensitive and drug resistant EGFR mutant cells exhibited differential growth kinetics with the drug resistant cells showing slower growth We incorporated these data into evolutionary mathematical cancer models with constraints derived from clinical data sets This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR mutant NSCLCs by delaying the development of resistance Footnotes Citation J Chmielecki J Foo G R Oxnard K Hutchinson K Ohashi R Somwar L Wang K R Amato M Arcila M L Sos N D Socci A Viale E de Stanchina M S Ginsberg R K Thomas M G Kris A Inoue M Ladanyi V A Miller F Michor W Pao Optimization of Dosing for EGFR Mutant Non Small Cell Lung Cancer with Evolutionary Cancer Modeling Sci Transl Med 3 90ra59 2011 Copyright 2011 American Association for the Advancement of Science View Full Text Science Translational Medicine Vol 3 Issue 90 06 July 2011 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Optimization of Dosing for EGFR Mutant Non Small Cell Lung Cancer with Evolutionary Cancer Modeling Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Optimization of Dosing for EGFR Mutant Non Small Cell Lung Cancer with Evolutionary Cancer Modeling By Juliann Chmielecki Jasmine Foo Geoffrey R Oxnard Katherine Hutchinson Kadoaki Ohashi Romel Somwar Lu Wang Katherine R Amato Maria Arcila Martin L Sos Nicholas D Socci Agnes Viale Elisa de Stanchina Michelle S Ginsberg Roman K Thomas Mark G Kris Akira Inoue Marc Ladanyi Vincent A Miller Franziska Michor William Pao Science Translational Medicine 06 Jul 2011 90ra59 Predictive models of EGFR mutant tumor behavior point to alternative drug dosing strategies to prevent and treat acquired resistance Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Optimization of Dosing for EGFR Mutant Non Small Cell Lung Cancer with Evolutionary Cancer Modeling By Juliann

    Original URL path: http://stm.sciencemag.org/content/3/90/90ra59 (2016-02-10)
    Open archived version from archive


  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors | Science Translational Medicine
    Bergethon A T Shaw S Gettinger A K Cosper S Akhavanfard R S Heist J Temel J G Christensen J C Wain T J Lynch K Vernovsky E J Mark M Lanuti A J Iafrate M Mino Kenudson J A Engelman Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Sci Transl Med 3 75ra26 2011 Copyright 2011 American Association for the Advancement of Science View Full Text Science Translational Medicine Vol 3 Issue 75 23 March 2011 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors By Lecia V Sequist Belinda A Waltman Dora Dias Santagata Subba Digumarthy Alexa B Turke Panos Fidias Kristin Bergethon Alice T Shaw Scott Gettinger Arjola K Cosper Sara Akhavanfard Rebecca S Heist Jennifer Temel James G Christensen John C Wain Thomas J Lynch Kathy Vernovsky Eugene J Mark Michael Lanuti A John Iafrate Mari Mino Kenudson Jeffrey A Engelman Science Translational Medicine 23 Mar 2011 75ra26 Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors By Lecia V Sequist Belinda A Waltman Dora Dias Santagata Subba Digumarthy Alexa B Turke Panos Fidias Kristin Bergethon Alice T Shaw Scott Gettinger Arjola K Cosper Sara Akhavanfard Rebecca S Heist Jennifer Temel James G Christensen John C Wain Thomas J Lynch Kathy Vernovsky Eugene J Mark Michael Lanuti A John Iafrate Mari Mino Kenudson Jeffrey A Engelman Science Translational Medicine 23 Mar 2011 75ra26 Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors Permalink Copy Related Content Research Article Blocking NRG1 and Other Ligand Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non Small Cell Lung Cancer Research Article Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti EGFR Therapy Research Article Improved Rodent Maternal Metabolism But Reduced Intrauterine Growth After Vertical Sleeve Gastrectomy Research Articles Quantitative Diagnosis of Malignant Pleural Effusions by Single Cell Mechanophenotyping Focus Mechanics Meets Medicine Research Article Structural Biochemical and Clinical Characterization of Epidermal Growth Factor Receptor EGFR Exon 20 Insertion Mutations in Lung Cancer Research Article Clonal status of actionable driver events and the timing of mutational processes in cancer evolution Focus Delineating cancer evolution with single cell sequencing Similar Articles in PubMed Google Scholar Cited By MM 151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations Transformation to small cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib Pruning Cancer s Evolutionary Tree with Lesion Directed Therapy Understanding the Pathway Impaired c Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non Small Cell Lung Cancer EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer Loss of Scribble Promotes Snail Translation through Translocation of HuR and Enhances Cancer Drug Resistance Management of advanced non small cell lung cancers with known mutations or rearrangements latest evidence and treatment approaches A basal stem cell signature identifies aggressive prostate cancer phenotypes Heightening Energetic Stress Selectively Targets LKB1 Deficient Non Small Cell Lung Cancers Evolutionary Precision Medicine A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK Rearranged Lung Adenocarcinoma Integrin alpha 6 beta 4 Promotes Autocrine Epidermal Growth Factor Receptor EGFR Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor HGF EGFR Kinase Domain Duplication EGFR KDD Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib Intratumoral Heterogeneity in EGFR Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition Mapping the Pathways of Resistance to Targeted Therapies Impact of Cell surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c MET Bispecific Antibody EGFR independent mechanisms of acquired resistance to AZD9291 in EGFR T790M positive NSCLC patients Next Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations The Allelic Context of the C797S Mutation Acquired upon Treatment with Third Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies Combined EGFR MEK Inhibition Prevents the Emergence of Resistance in EGFR Mutant Lung Cancer Phase I dose escalation study of the PI3K mTOR inhibitor voxtalisib SAR245409 XL765 plus temozolomide with or without radiotherapy in patients with high grade glioma Activation of the BMP BMPR pathway conferred resistance to EGFR TKIs in lung squamous cell carcinoma patients with EGFR mutations Experience with erlotinib in the treatment of non small cell lung cancer Clinical Utility of Patient Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR Mutant Lung Adenocarcinoma Origins genetic landscape and emerging therapies of small cell lung cancer Heterogeneity Underlies the Emergence of EGFRT790 Wild Type Clones Following Treatment of T790M Positive Cancers with

    Original URL path: http://stm.sciencemag.org/content/3/75/75ra26 (2016-02-10)
    Open archived version from archive

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab | Science Translational Medicine
    Kazuhiko Nakagawa Find this author on Google Scholar Find this author on PubMed Search for this author on this site Pasi A Jänne Find this author on Google Scholar Find this author on PubMed Search for this author on this site Article Figures Data Info Metrics eLetters PDF You are currently viewing the View Full Text As a service to the community AAAS Science has made this article free with registration Username Enter your Sciencemag org username Password Enter the password that accompanies your username Forgot your username or password Log in Register for Free Join Subscribe Recommend a subscription to your library Help for librarians Science Translational Medicine Vol 3 Issue 99 07 September 2011 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro Fukuoka Marileila Varella Garcia Kazuhiko Nakagawa Pasi A Jänne Science Translational Medicine 07 Sep 2011 99ra86 Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1 2 stimulated growth Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro

    Original URL path: http://stm.sciencemag.org/content/3/99/99ra86.figures-only (2016-02-10)
    Open archived version from archive

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab | Science Translational Medicine
    dx doi org 10 1126 scitranslmed 3002442 PubMed 21900593 Published By American Association for the Advancement of Science Print ISSN 1946 6234 Online ISSN 1946 6242 History Received for publication 25 March 2011 Accepted for publication 15 July 2011 Copyright Usage Copyright 2011 American Association for the Advancement of Science Author Information Kimio Yonesaka 1 2 3 4 Kreshnik Zejnullahu 1 2 Isamu Okamoto 3 Taroh Satoh 3 Federico Cappuzzo 5 John Souglakos 6 7 Dalia Ercan 1 2 Andrew Rogers 1 2 Massimo Roncalli 5 Masayuki Takeda 3 Yasuhito Fujisaka 3 Juliet Philips 2 Toshio Shimizu 3 Osamu Maenishi 8 Yonggon Cho 9 Jason Sun 1 2 Annarita Destro 5 Koichi Taira 10 Koji Takeda 10 Takafumi Okabe 1 2 Jeffrey Swanson 1 2 Hiroyuki Itoh 8 Minoru Takada 11 Eugene Lifshits 12 Kiyotaka Okuno 13 Jeffrey A Engelman 12 Ramesh A Shivdasani 2 14 Kazuto Nishio 15 Masahiro Fukuoka 4 11 Marileila Varella Garcia 9 Kazuhiko Nakagawa 3 and Pasi A Jänne 1 2 14 1 Lowe Center for Thoracic Oncology Dana Farber Cancer Institute Boston MA 02215 USA 2 Department of Medical Oncology Dana Farber Cancer Institute Boston MA 02215 USA 3 Department of Medical Oncology Kinki University School of Medicine Osaka 589 8511 Japan 4 Department of Medical Oncology Izumi Municipal Hospital Osaka 594 0071 Japan 5 Istituto Clinico Humanitas Rozzano 20089 Italy 6 Laboratory of Tumor Biology Medical School University of Crete Heraklion 71110 Greece 7 University Hospital of Heraklion Heraklion 71110 Greece 8 Department of Pathology Kinki University School of Medicine Osaka 589 8511 Japan 9 University of Colorado Cancer Center Aurora CO 80045 USA 10 Department of Clinical Oncology Osaka City General Hospital Osaka 534 0021 Japan 11 Department of Medical Oncology Kinki University School of Medicine Sakai Hospital Osaka 590 0132 Japan 12 Massachusetts General Hospital Cancer Center Boston MA 02129 USA 13 Department of Surgery Kinki University School of Medicine Osaka 589 8511 Japan 14 Department of Medicine Brigham and Women s Hospital and Harvard Medical School Boston MA 02115 USA 15 Department of Genome Biology Kinki University School of Medicine Osaka 589 8511 Japan To whom correspondence should be addressed E mail nakagawa at med kindai ac jp K N pjanne at partners org P A J AltMetrics No Altmetric data available for this article Article usage Abstract Full PDF Sep 2011 10085 468 1264 Oct 2011 1317 84 243 Nov 2011 814 54 177 Dec 2011 446 32 84 Jan 2012 448 28 85 Feb 2012 423 38 102 Mar 2012 430 17 81 Apr 2012 295 14 59 May 2012 378 11 51 Jun 2012 201 9 32 Jul 2012 255 29 32 Aug 2012 311 8 42 Sep 2012 183 18 21 Oct 2012 168 25 32 Nov 2012 157 15 18 Dec 2012 169 20 25 Jan 2013 139 18 28 Feb 2013 136 15 16 Mar 2013 178 23 18 Apr 2013 223 25 32 May 2013 162 21 15 Jun 2013 211 17 24 Jul 2013 100 10 18 Aug 2013 176 24 37 Sep 2013 202 21 31 Oct 2013 189 28 23 Nov 2013 126 15 16 Dec 2013 198 21 41 Jan 2014 179 19 20 Feb 2014 178 15 33 Mar 2014 178 15 25 Apr 2014 146 22 31 May 2014 157 16 23 Jun 2014 139 15 18 Jul 2014 111 12 19 Aug 2014 91 13 13 Sep 2014 121 17 22 Oct 2014 143 20 18 Nov 2014 101 18 17 Dec 2014 114 8 7 Jan 2015 209 22 30 Feb 2015 112 29 17 Mar 2015 135 13 20 Apr 2015 115 25 22 May 2015 96 16 21 Jun 2015 120 7 24 Jul 2015 76 7 15 Aug 2015 42 16 13 Sep 2015 56 9 16 Oct 2015 27 9 24 Nov 2015 21 6 30 Dec 2015 39 4 19 Jan 2016 146 11 22 Feb 2016 43 5 6 View Full Text Science Translational Medicine Vol 3 Issue 99 07 September 2011 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro Fukuoka Marileila Varella Garcia Kazuhiko Nakagawa Pasi A Jänne Science Translational Medicine 07 Sep 2011 99ra86 Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1 2 stimulated growth Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka

    Original URL path: http://stm.sciencemag.org/content/3/99/99ra86.article-info (2016-02-10)
    Open archived version from archive

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab | Science Translational Medicine
    text No HTML tags allowed Web page addresses and e mail addresses turn into links automatically Lines and paragraphs break automatically Upload Tables and Figures Attach tables e g doc and figures jpg gif tif by choosing the desired file and then uploading them below Add a new file Upload Files must be less than 100 MB Allowed file types doc jpg jpeg gif tif pdf File names can only contain the following characters A Z a z 0 9 Author Information Contributors First name and middle name First or given name e g Peter Last Name Your last or family name e g MacMoody Email Your email address e g higgs boson gmail com Role Occupation Your role and or occupation e g Orthopedic Surgeon Affiliation Your organization or institution if applicable e g Royal Free Hospital Add another contributor optional Statement of Competing Interests Competing interests Yes No Please describe the competing interests Highwire Comment Subject Apath Vertical Tabs Submit No eLetters have been published for this article View Full Text Science Translational Medicine Vol 3 Issue 99 07 September 2011 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro Fukuoka Marileila Varella Garcia Kazuhiko Nakagawa Pasi A Jänne Science Translational Medicine 07 Sep 2011 99ra86 Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1 2 stimulated growth Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Activation of ERBB2 Signaling Causes Resistance

    Original URL path: http://stm.sciencemag.org/content/3/99/99ra86.e-letters (2016-02-10)
    Open archived version from archive

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab | Science Translational Medicine
    author on PubMed Search for this author on this site Pasi A Jänne Find this author on Google Scholar Find this author on PubMed Search for this author on this site Article Figures Data Info Metrics eLetters PDF Log in to view full text As a service to the community AAAS Science has made this article free with registration Username Enter your Sciencemag org username Password Enter the password that accompanies your username Forgot your username or password Log in Register for Free Join Subscribe Recommend a subscription to your library Help for librarians Science Translational Medicine Vol 3 Issue 99 07 September 2011 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro Fukuoka Marileila Varella Garcia Kazuhiko Nakagawa Pasi A Jänne Science Translational Medicine 07 Sep 2011 99ra86 Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1 2 stimulated growth Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro Fukuoka Marileila Varella Garcia Kazuhiko Nakagawa Pasi A Jänne Science Translational Medicine

    Original URL path: http://stm.sciencemag.org/content/3/99/99ra86.full (2016-02-10)
    Open archived version from archive

  • Table of Contents — September 07, 2011, 3 (99) | Science Translational Medicine
    Peow Bobby Tan Cheng William Hong Abdul Qader O Al Aidaroos Leyon Varghese Caixia Huang Qi Zeng Science Translational Medicine 07 Sep 2011 99ra85 Antibody therapy can target intracellular proteins Editor s Summary Abstract Full Text PDF Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro Fukuoka Marileila Varella Garcia Kazuhiko Nakagawa Pasi A Jänne Science Translational Medicine 07 Sep 2011 99ra86 Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1 2 stimulated growth Editor s Summary Abstract Full Text PDF Lysophosphatidic Acid Signaling May Initiate Fetal Hydrocephalus By Yun C Yung Tetsuji Mutoh Mu En Lin Kyoko Noguchi Richard R Rivera Ji Woong Choi Marcy A Kingsbury Jerold Chun Science Translational Medicine 07 Sep 2011 99ra87 Blockade of lysophosphatidic acid signaling provides a new strategy for treating fetal hydrocephalus Editor s Summary Abstract Full Text PDF Editors Choice Vitamin D May Do the Uterus Good By Ruth M Farrell Science Translational Medicine 07 Sep 2011 99ec143 Agents that alter cytokine production by uterine lining cells might help to stem immune mediated miscarriage Full Text Neurons Are Only Skin Deep By Diane Gesty Palmer Science Translational Medicine 07 Sep 2011 99ec144 Skin fibroblasts from patients with Alzheimer s disease can be converted directly into neuronal cells that retain the cellular characteristics of the disease Full Text Coffee Perks Up Parkinson s Disease Prevention By Carrie M Nielson Science Translational Medicine 07 Sep 2011 99ec145 Among heavy coffee drinkers a glutamate receptor gene polymorphism halves the risk of developing Parkinson s disease Full Text Thinking Globally About Asthma By Timothy B Niewold Science Translational Medicine 07 Sep 2011 99ec146 Genome wide association studies reveal shared and unique risk factors for asthma in ethnically diverse North American populations Full Text The Midas Touch By Srini Tridandapani Science Translational Medicine 07 Sep 2011 99ec147 A gold gadolinium label can be used to track encapsulated pancreatic islets after transplantation Full Text Podcast Science Translational Medicine Podcast 7 September 2011 By Jerold Chun Orla Smith Science Translational Medicine 07 Sep 2011 99pc10 A conversation with Jerold Chun about identification of a lipid in blood that may trigger hydrocephalus in the fetus Abstract More From Science Translational Medicine Current Table of Contents Archive In the Pipeline About Science Translational Medicine Mission and Scope Editors and Advisory Boards Editorial Policies Information for Authors Information for Reviewers Staff Contact Us Subscribe Submit About The Cover ONLINE COVER Triggering Hydrocephalus Using a new mouse model Yung et al identify a blood borne lipid LPA lysophosphatidic acid that may trigger development of hydrocephalus a disorder of newborns

    Original URL path: http://stm.sciencemag.org/content/3/99 (2016-02-10)
    Open archived version from archive

  • Table of Contents — September 07, 2011, 3 (99) | Science Translational Medicine
    Cheng Peow Bobby Tan Cheng William Hong Abdul Qader O Al Aidaroos Leyon Varghese Caixia Huang Qi Zeng Science Translational Medicine 07 Sep 2011 99ra85 Antibody therapy can target intracellular proteins Editor s Summary Abstract Full Text PDF Activation of ERBB2 Signaling Causes Resistance to the EGFR Directed Therapeutic Antibody Cetuximab By Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh Federico Cappuzzo John Souglakos Dalia Ercan Andrew Rogers Massimo Roncalli Masayuki Takeda Yasuhito Fujisaka Juliet Philips Toshio Shimizu Osamu Maenishi Yonggon Cho Jason Sun Annarita Destro Koichi Taira Koji Takeda Takafumi Okabe Jeffrey Swanson Hiroyuki Itoh Minoru Takada Eugene Lifshits Kiyotaka Okuno Jeffrey A Engelman Ramesh A Shivdasani Kazuto Nishio Masahiro Fukuoka Marileila Varella Garcia Kazuhiko Nakagawa Pasi A Jänne Science Translational Medicine 07 Sep 2011 99ra86 Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1 2 stimulated growth Editor s Summary Abstract Full Text PDF Lysophosphatidic Acid Signaling May Initiate Fetal Hydrocephalus By Yun C Yung Tetsuji Mutoh Mu En Lin Kyoko Noguchi Richard R Rivera Ji Woong Choi Marcy A Kingsbury Jerold Chun Science Translational Medicine 07 Sep 2011 99ra87 Blockade of lysophosphatidic acid signaling provides a new strategy for treating fetal hydrocephalus Editor s Summary Abstract Full Text PDF Editors Choice Vitamin D May Do the Uterus Good By Ruth M Farrell Science Translational Medicine 07 Sep 2011 99ec143 Agents that alter cytokine production by uterine lining cells might help to stem immune mediated miscarriage Full Text Neurons Are Only Skin Deep By Diane Gesty Palmer Science Translational Medicine 07 Sep 2011 99ec144 Skin fibroblasts from patients with Alzheimer s disease can be converted directly into neuronal cells that retain the cellular characteristics of the disease Full Text Coffee Perks Up Parkinson s Disease Prevention By Carrie M Nielson Science Translational Medicine 07 Sep 2011 99ec145 Among heavy coffee drinkers a glutamate receptor gene polymorphism halves the risk of developing Parkinson s disease Full Text Thinking Globally About Asthma By Timothy B Niewold Science Translational Medicine 07 Sep 2011 99ec146 Genome wide association studies reveal shared and unique risk factors for asthma in ethnically diverse North American populations Full Text The Midas Touch By Srini Tridandapani Science Translational Medicine 07 Sep 2011 99ec147 A gold gadolinium label can be used to track encapsulated pancreatic islets after transplantation Full Text Podcast Science Translational Medicine Podcast 7 September 2011 By Jerold Chun Orla Smith Science Translational Medicine 07 Sep 2011 99pc10 A conversation with Jerold Chun about identification of a lipid in blood that may trigger hydrocephalus in the fetus Abstract More From Science Translational Medicine Current Table of Contents Archive In the Pipeline About Science Translational Medicine Mission and Scope Editors and Advisory Boards Editorial Policies Information for Authors Information for Reviewers Staff Contact Us Subscribe Submit About The Cover ONLINE COVER Triggering Hydrocephalus Using a new mouse model Yung et al identify a blood borne lipid LPA lysophosphatidic acid that may trigger development of hydrocephalus a disorder of

    Original URL path: http://stm.sciencemag.org/content/3/99.toc (2016-02-10)
    Open archived version from archive



  •